NuVasive

OverviewSuggest Edit

NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. Its principal product offering is based on its Maximum Access Surgery, or MAS platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. 
TypePublic
Founded1997
HQSan Diego, CA, USMap
Websitenuvasive.com
Employee Ratings4.1More
Overall CultureBMore
View Jobs (160)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)2,800(+8%)
Job Openings160
Revenue (FY, 2020)$1.1 B(-10%)
Share Price (Apr 2021)$65.9(-1%)
Cybersecurity ratingCMore

Key People/Management at NuVasive

Matt Harbaugh

Matt Harbaugh

Executive Vice President and Chief Financial Officer
Gregory T. Lucier

Gregory T. Lucier

Director
Dale Wolf

Dale Wolf

Senior Vice President, Global Operations
Brent Boucher

Brent Boucher

Executive Vice President, Global Commercial
Lucas Vitale

Lucas Vitale

Senior Vice President and Chief Human Resources Officer
Nathaniel Sisitsky

Nathaniel Sisitsky

Senior Vice President, General Counsel and Corporate Secretary
Show more

NuVasive Office Locations

NuVasive has offices in San Diego, Aliso Viejo, Columbia, Fairborn and in 14 other locations
San Diego, CA, US (HQ)
7475 Lusk Blvd
Aliso Viejo, CA, US
101 Enterprise #100
Columbia, MD, US
10420 Little Patuxent Pkwy #250
Fairborn, OH, US
1 Herald Square
Memphis, TN, US
4670 E Shelby Dr #101
Kew, AU
620 High St
Show all (20)

NuVasive Financials and Metrics

NuVasive Revenue

Embed Graph
View revenue for all periods
NuVasive's revenue was reported to be $1.05 b in FY, 2020
USD

Revenue (FY, 2020)

1.1b

Gross profit (FY, 2020)

729.0m

Gross profit margin (FY, 2020), %

69.4%

Net income (FY, 2020)

(37.2m)

Market capitalization (7-Apr-2021)

3.4b

Closing stock price (7-Apr-2021)

65.9

Cash (31-Dec-2020)

856.9m

EV

4.1b
NuVasive's current market capitalization is $3.4 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014Y, 2014Y, 2015FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

478.2m540.5m620.3m685.2m762.4m762.4m811.1m811.1m962.1m1.0b1.1b1.2b1.1b

Revenue growth, %

11%6%19%

Cost of goods sold

85.1m112.1m153.4m180.5m182.4m182.4m194.5m194.5m240.1m269.0m311.2m312.4m321.6m

Gross profit

393.1m428.4m466.8m504.7m580.1m580.1m616.6m616.6m722.0m760.5m790.6m855.7m729.0m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

119.6m120.3m124.5m133.0m132.9m151.7m154.4m148.4m159.5m165.7m169.2m177.5m190.7m189.9m192.4m202.9m200.5m215.1m236.2m239.6m249.9m260.6m247.4m260.5m281.6m271.3m274.8m292.1m290.8m259.9m203.6m295.3m

Cost of goods sold

21.0m21.6m23.5m25.5m26.0m36.9m36.5m37.7m39.1m48.7m43.3m43.3m44.8m47.7m45.7m48.4m49.2m54.2m59.7m59.2m61.6m66.4m65.6m73.8m77.1m74.2m74.5m77.6m77.0m71.9m80.5m84.6m

Gross profit

98.6m98.7m100.9m107.5m106.9m114.8m117.9m110.6m120.4m117.0m125.9m134.2m145.8m142.2m146.7m154.5m151.4m160.9m176.5m180.5m188.3m194.2m181.8m186.7m204.5m197.1m200.3m214.5m213.8m188.0m123.1m210.6m

Gross profit Margin, %

82%82%81%81%80%76%76%75%75%71%74%76%76%75%76%76%75%75%75%75%75%75%73%72%73%73%73%73%74%72%60%71%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

92.6m163.5m123.3m102.8m142.4m192.3m153.6m72.8m117.8m213.0m856.9m

Accounts Receivable

76.6m88.4m89.0m104.8m119.0m127.6m199.0m196.5m211.5m207.1m

Prepaid Expenses

19.9m8.5m10.9m21.6m8.8m18.8m13.7m16.9m19.7m

Inventories

107.6m119.3m126.3m136.9m154.6m168.1m208.2m247.2m273.2m312.4m300.6m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

67.5m70.6m134.1m505.1m220.9m270.2m121.2m107.7m78.5m58.9m100.6m110.8m106.5m130.7m88.5m78.6m141.3m270.1m263.1m203.8m134.0m130.9m62.2m73.7m70.1m75.1m93.4m128.4m163.4m512.0m796.8m774.5m

Accounts Receivable

68.2m71.6m76.0m80.5m78.6m85.6m85.7m78.1m90.4m96.3m96.2m106.3m112.6m108.4m111.5m116.8m115.6m126.1m141.9m143.8m172.1m190.2m187.2m188.1m199.9m191.6m194.4m208.0m203.6m186.8m182.1m205.3m

Prepaid Expenses

4.7m5.1m9.2m8.1m7.3m9.1m9.0m10.1m11.3m11.8m10.2m9.0m8.4m7.3m7.8m8.1m9.6m12.9m12.3m9.2m21.1m23.6m23.4m13.6m14.6m14.6m17.3m17.7m15.6m

Inventories

93.1m98.8m114.4m118.0m122.6m122.0m128.6m133.0m129.6m137.4m140.7m147.7m157.4m159.7m163.4m163.7m164.9m200.7m201.9m212.8m223.1m236.8m249.0m258.0m259.8m271.3m288.5m297.1m308.9m324.7m312.2m305.6m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

78.3m(69.8m)3.1m7.0m(17.5m)65.3m35.4m81.3m12.5m65.2m(37.2m)

Depreciation and Amortization

36.7m36.2m51.9m63.1m82.3m83.8m125.4m141.7m149.9m135.6m140.9m

Inventories

(18.7m)(17.2m)(11.0m)(21.0m)(21.3m)(26.0m)(22.6m)(35.3m)(38.6m)(54.9m)(40.8m)

Accounts Payable

11.6m(3.4m)2.9m21.8m22.3m7.7m11.9m(5.6m)20.5m(3.3m)8.8m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

7.8m16.4m2.4m7.7m(59.8m)673.0k3.5m5.9m851.0k(5.6m)1.9m(18.3m)(22.4m)(24.2m)31.4m41.4m54.2m(9.3m)26.0m29.5m12.3m24.6m57.7m(27.1m)(15.6m)322.0k9.4m24.3m35.4m5.3m(44.7m)(38.8m)

Depreciation and Amortization

17.1m27.4m7.8m15.9m24.8m12.1m25.3m38.2m14.6m30.3m46.3m15.4m31.0m46.5m20.4m41.4m62.3m26.3m57.3m90.7m34.9m69.6m104.6m37.0m74.1m111.4m39.3m78.1m101.2m35.0m70.1m106.1m

Inventories

(4.3m)(10.0m)(6.7m)(12.1m)(19.9m)(3.5m)(11.0m)14.2m(4.1m)(13.7m)(16.7m)(11.7m)(20.9m)(27.2m)(11.4m)(15.2m)(19.8m)9.4m12.0m(22.4m)(13.6m)(29.0m)(36.2m)(12.1m)(19.6m)(33.5m)(19.3m)(31.9m)(45.6m)(21.1m)(33.0m)(37.5m)

Accounts Payable

4.6m6.3m4.0m(2.3m)504.0k7.8m7.1m4.5m10.4m8.8m10.4m4.5m5.1m16.0m17.4m6.8m8.8m10.0m14.3m5.9m593.0k5.0m(5.9m)1.6m9.0m21.7m(2.5m)9.3m7.4m(5.3m)1.3m10.2m
show all
USDQ2, 2010

Financial Leverage

2.1 x
Show all financial metrics

NuVasive Acquisitions / Subsidiaries

Company NameDateDeal Size
SafePassageDecember 12, 2017
Biotronic NeuroNetworkJune 06, 2016$98 m
Ellipse TechnologiesJanuary 05, 2016$410 m

NuVasive Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

Learn more about our premium products
SecurityScorecard logo

NuVasive Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

NuVasive Online and Social Media Presence

NuVasive's Trends

Embed Graph

NuVasive Company Culture

  • Overall Culture

    B

    75/100

  • CEO Rating

    B

    73/100

  • Compensation

    D

    54/100

Learn more on Comparably

NuVasive News and Updates

March 16, 2021

NuVasive and the International Spine Study Group Foundation Announce Expanded Long-Term Partnership with Initiation of Additional Clinical Studies

SAN DIEGO, March 16, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, and the International Spine Study Group Foundation (ISSGF) today...
February 08, 2021

NuVasive Expands Clinical Professional Development Program with New East Coast Experience Center in New York Metropolitan Area

SAN DIEGO, Feb. 8, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the expansion of the Company's Clinical Professional...
December 07, 2020

NuVasive to Feature its C360 Portfolio at the Cervical Spine Research Society 48th Annual Meeting

SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a silver level sponsor and feature...
October 27, 2020

NuVasive to Participate as Gold Level Sponsor at SMISS Annual Forum

SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a gold level sponsor at the Society...
October 26, 2020

Cell Therapy Market New Business Experts Ideas By Kolon TissueGene, MEDIPOST, NuVasive, Fibrocell Science, Cells for Cells

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is …
September 09, 2020

NuVasive Expands Precice Portfolio with First-of-its-Kind Plate for Pediatric Limb Lengthening and Reconstruction Procedures

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the limited availability of the new Precice® Plate for use...
Show more

NuVasive Blogs

April 13, 2021

NuVasive Patient Success Story: Andy

Since its inception in 2010, NuVasive’s the Better Way Back (TBWB) program has been committed to raising public awareness of spine disorders and educating patients, loved ones, clinicians, and healthcare providers about treatment options, including surgery. Changing patient lives and empowering pati…
April 06, 2021

NuVasive's Simplify Disc Receives FDA Approval for Two-Level Cervical Total Disc Replacement

NuVasive's Simplify Disc Receives FDA Approval for Two-Level Cervical Total Disc Replacement Content Import Tue, 04/06/2021 - 16:03 NuVasive's Simplify Disc Receives FDA Approval for Two-Level Cervical Total Disc Replacement April 06, 2021 This release is a b…
March 25, 2021

NuVasive Announces Retirement of Gregory T. Lucier from Board of Directors

NuVasive Announces Retirement of Gregory T. Lucier from Board of Directors marco.guevara@… Thu, 03/25/2021 - 16:03 NuVasive Announces Retirement of Gregory T. Lucier from Board of Directors March 25, 2021 This release is a backfill from a News Wire …
March 25, 2021

Featured Case: Prone single-position surgery with XLIF Prone and MAS TLIF

In our Featured Case series, NuVasive highlights outcome driven innovation, and the combination of access, interbody implants, biologics, fixation and enabling technologies to create a comprehensive system to address patient pathologies. In this featured case, Dr. Sushil Basra, Long Island Spine Spe…
March 10, 2021

TBWB Patient Success Story: Henry

Since its inception in 2010, NuVasive’s the Better Way Back (TBWB) program has been committed to raising public awareness of spine disorders and educating patients, loved ones, clinicians, and healthcare providers about treatment options, including surgery. Changing patient lives and empowering pati…
March 10, 2021

Featured Case: MIS TLIF with partial posterior ALL release using TLX 20°, Reline MAS reduction and Osteocel Pro

In our Featured Case series, NuVasive highlights outcome driven innovation, and the combination of access, interbody implants, biologics, fixation and enabling technologies to create a comprehensive system to address patient pathologies. Dr. Javier Garcia-Bengochea, Neurosurgeon, Baptist Health, uti…
Show more

 NuVasive Frequently Asked Questions

  • When was NuVasive founded?

    NuVasive was founded in 1997.

  • Who are NuVasive key executives?

    NuVasive's key executives are Matt Harbaugh, Gregory T. Lucier and Dale Wolf.

  • How many employees does NuVasive have?

    NuVasive has 2,800 employees.

  • What is NuVasive revenue?

    Latest NuVasive annual revenue is $1.1 b.

  • What is NuVasive revenue per employee?

    Latest NuVasive revenue per employee is $375.2 k.

  • Who are NuVasive competitors?

    Competitors of NuVasive include Stryker, Integra LifeSciences and Cook Medical.

  • Where is NuVasive headquarters?

    NuVasive headquarters is located at 7475 Lusk Blvd, San Diego.

  • Where are NuVasive offices?

    NuVasive has offices in San Diego, Aliso Viejo, Columbia, Fairborn and in 14 other locations.

  • How many offices does NuVasive have?

    NuVasive has 20 offices.